Institutional members access full text with Ovid®

Share this article on:

131I Therapy Using rhTSH Stimulation and Dosimetry in Metastatic Malignant Struma Ovarii

Yan, Jinchun MD, PhD*; Lewis, David H. MD*; Benoit, Michelle F. MD; Eary, Janet F. MD*; Mankoff, David A. MD, PhD

doi: 10.1097/RLU.0b013e3182a75cad
Interesting Images

Abstract: A 38-year-old woman with metastatic malignant struma ovarii, including massive liver metastases and retroperitoneal lymphadenopathy, underwent ovarian resection and retroperitoneal lymph nodes excision, partial hepatectomy, and radiofrequency ablation for liver metastases. She underwent thyroidectomy and received three 131I treatments using recombinant human thyrotropin stimulation and radioiodine dosimetry. posttherapy 131I imaging, anatomic images, and thyroglobulin levels showed significant diminution in the tumor burdens and remarkable decline in thyroglobulin levels. This case provided valuable information on recombinant human thyrotropin-assisted 131I ablation in conjunction with dosimetry in an unusual presentation of iodine-avid malignant struma ovarii with bulky metastases.

From the *Department of Radiology, University of Washington Medical Center, Seattle; †Division of Gynecologic Oncology, Group Health Bellevue Medical Center, Bellevue, WA; and ‡Division of Nuclear Medicine & Clinical Molecular Imaging, Department of Radiology, Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, PA.

Received for publication May 13, 2013; and revision accepted July 10, 2013.

Conflicts of interest and sources of funding: none declared.

Reprints: David A. Mankoff, MD, PhD, Division of Nuclear Medicine & Clinical Molecular Imaging, Department of Radiology, Hospital of the University of Pennsylvania, University of Pennsylvania, 116 Donner Building, HUP, 3400 Spruce St, Philadelphia, PA 19104-4283. E-mail: david.mankoff@uphs.upenn.edu.

© 2014 by Lippincott Williams & Wilkins